Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15131517 | 0.83 | MAPT (0.55) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL10384384 | 0.80 | KMT2A (0.47) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL4678382 | 0.80 | MEN1 (0.49) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL4682287 | 0.80 | KMT2A (0.51) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL1185790 | 0.79 | IDO1 (0.61) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL7873180 | 0.79 | MAPT (0.58) | MAPTALDH1A1KMT2AMEN1IDO1 | |
| SCHEMBL24726744 | 0.78 | CYP1A2 (0.46) | MAPTALDH1A1KMT2AMEN1ABCC9 | |
| SCHEMBL18520538 | 0.78 | CYP1A2 (0.46) | MAPTALDH1A1KMT2AMEN1ABCC9 | |
| SCHEMBL4259667 | 0.78 | CYP1A2 (0.46) | MAPTALDH1A1KMT2AMEN1ABCC9 | |
| Hydrochloric Acid SCHEMBL2546143 | 0.78 | IDO1 (0.59) | MAPTALDH1A1KMT2AMEN1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| EP-2800743-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9656999-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | MAPT 3043/4885ALDH1A1 1337/4885KMT2A 3613/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MAPT 3808/4885ALDH1A1 923/4885KMT2A 2484/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | MAPT 3808/4885ALDH1A1 923/4885KMT2A 2484/4885 |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MAPT 3808/4885ALDH1A1 923/4885KMT2A 2484/4885 |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MAPT 3808/4885ALDH1A1 923/4885KMT2A 2484/4885 |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | MAPT 3808/4885ALDH1A1 923/4885KMT2A 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.